Key Oncology Highlights from 2025 | Dr Suleka AR from ⁨@oncoassist⁩

???? Oncology Updates | Dr. Suleka AR

In this Oncology Updates video, Dr. Suleka AR, Medical Advisor at ONCOassist, walks through the most important oncology developments from 2025, highlighting trends that are actively shaping cancer care worldwide.

???? What’s covered:
- Practice-changing clinical trial results across tumor types
- Rapid expansion of precision oncology and biomarker-driven care
- Growing role of antibody-drug conjugates (ADCs) and targeted therapies
- Shifts in treatment sequencing and standards of care
- Safety, access, and real-world implementation challenges
- What these updates mean for clinicians and patients today

This concise overview helps oncology professionals stay aligned with where the field is heading and what matters most right now.

Reference Links:

1. Bardia, A., et al (2025). Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of Clinical Oncology, 43(3), 285–296. https://doi.org/10.1200/jco.24.00920
2. Cercek, A. et al, (2025). Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine, 392(23), 2297–2308. https://doi.org/10.1056/nejmoa2404512
3. Adkins, D., et al (2025). Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. Journal of Clinical Oncology, 43(16_suppl), 6012–6012. https://doi.org/10.1200/jco.2025.43.16_suppl.6012
4. Qi, C., et al (2025). Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. The Lancet, 405(10494), 2049–2060. https://doi.org/10.1016/s0140-6736(25)00860-8
5. Aldea, M. et al, (2025). ESMO basic requirements for AI-based biomarkers in oncology (EBAI). Annals of Oncology. https://doi.org/10.1016/j.annonc.2025.11.009

---------------------------------------------------

???? Oncology at your fingertips.
Download the ONCOassist app:
???? iOS: https://apple.co/4iuMxfS
???? Android: https://bit.ly/oncoassistonandroid
????Webapp: https://bit.ly/ONCOassistOnWeb

???? Learn more at: https://oncoassist.com/
???? SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!
???? Turn on notifications so you never miss an episode.
???? FOLLOW US FOR UPDATES:
???? LinkedIn: https://bit.ly/oncoassistlinkedin
???? Twitter/X: https://bit.ly/oncoassisttwitter

#OncologyUpdates #MedicalOncology #PrecisionOncology #CancerCare #ONCOassist #OncologyTrends #Oncoalert #Oncology